Medical
Therapeutic Stock Aethlon Medical, Inc. (NASDAQ: $AEMD) Gains on Hemopurifier Bird Flu Update
Investorideas.com (www.investorideas.com) a go-to platform for
big investing ideas for stock traders, including biotech and medical tech stocks reports on trading and
news for Aethlon
Medical, Inc.
(Nasdaq: AEMD), a medical therapeutic company focused on
developing products to treat cancer and life-threatening infectious diseases.
The stock has had big gains in this morning’s
trading session following an update on the company’s Hemopurifier device in the treatment of Bird Flu.
The stock is trading at $0.5761, up 0.1427,
gaining 32.7745% on volume of over 55 Million shares as of this report. The
stock had a day’s high of $0, 8275.
Today Aethlon provided a statement of its investigational
medical device with respect to H5N1 avian influenza "Bird Flu."
Aethlon has recently received a number of inquiries
regarding the potential utility of its Hemopurifier device in the treatment of
Bird Flu. These inquiries come on the heels of the reporting of isolation of
Bird Flu in dairy cows, 60 human cases in eight states including a case of
severe infection in Louisiana, and yesterday's declaration of a state of
emergency in California.
Paid News Dissemination of behalf of
AEMD.
Read this news, featuring AEMD in
full at https://www.investorideas.com/news/2024/biotech/12201AEMD-Hemopurifier-Bird-Flu-Update.asp
The Aethlon Hemopurifier is an investigational
extracorporeal medical device designed to remove enveloped viruses and
extracellular vesicles from the bloodstream. The device incorporates plasma
separation, size exclusion, and affinity binding to a proprietary resin
containing the plant lectin Galanthus nivalis agglutinin (GNA) bound to a medical
grade diatomaceous earth. Enveloped viruses and extracellular vesicles contain
the sugar mannose on their surface, which is the therapeutic target of the GNA.
Aethlon has previously contracted Battelle labs to examine
the in vitro removal of influenza viruses including H5N1 by a scaled down
version of the Aethlon Hemopurifier. In this experiment, cell culture media was
spiked with the H5N1 virus and continuously circulated over the device. Samples
were taken periodically to examine viral removal by the device. In this study,
a miniature version of the device removed 99% of H5N1 following 6 hours of
treatment.
While the Aethlon Hemopurifier has not yet been used to
treat patients with severe influenza, including those infected with H5N1, it
has been used in 38 patients across 164 distinct treatment sessions, targeting
diseases such as hepatitis C, HIV, and in patients critically ill due to
COVID-19 and Ebola. The Hemopurifier has a "breakthrough device"
designation with the FDA for life-threatening viruses for which there is no
effective treatment.
Current treatment guidelines from the Center for Disease
Control and Prevention
(https://www.cdc.gov/bird-flu/hcp/novel-av-treatment-guidance/), for
hospitalized patients with suspected Bird Flu (H5N1), are to initiate antiviral
therapy as soon as possible with Oseltamivir, with or without combination
therapy with Baloxavir. Clinical failures during Oseltamavir therapy due to the
development of antiviral resistance have been observed in hospitalized patients
with H5N1. This phenomenon raises the possibility that novel treatment
strategies may be required. Aethlon Medical will monitor this situation closely
and interact with hospitals, the state of California, and the FDA as
appropriate if cases mount and currently available treatments are not
effective.
Recent news
https://www.investorideas.com/news/2024/12201AEMD-Hemopurifier-H5N1-Bird-Flu.asp
Biotech stocks
to watch:
Research more Biotech and medical technology
stocks with Investorideas.com free stock directory
About Investorideas.com - Big
Investing Ideas
Investorideas.com is the go-to platform for big investing ideas. From
breaking stock news to top-rated investing podcasts, we cover it all. Our
original branded content includes podcasts such as Exploring Mining, Cleantech,
Crypto Corner, Cannabis News, and the AI Eye. We also create free investor
stock directories for sectors including mining, crypto, renewable energy,
gaming, biotech, tech, sports and more. Public companies within the sectors we
cover can use our news publishing and content creation services to help tell
their story to interested investors.
Disclaimer/Disclosure: This
news alert for AEMD is part of Investorideas.com paid
content on behalf of Aethlon Medical. Nothing
on our sites should be construed as an offer or solicitation to buy or sell
products or securities. All investing involves risk and possible losses. This
site is currently compensated for news publication and distribution, social
media and marketing, content creation and more. Contact management and IR of
each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp
Global investors must adhere to
regulations of each country. Please read Investorideas.com privacy poilicy: https://www.investorideas.com/About/Private_Policy.asp
Learn more about our news, IR, PR and
social media, podcast sponsorship and ticker tag content creation services at
Investorideas.com
https://www.investorideas.com/Investors/Services.asp
Learn more about digital advertising
and guest posts/sponsored posts
https://www.investorideas.com/Advertise/
Follow us on X @investorideas @stocknewsbites
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on YouTube https://www.youtube.com/c/Investorideas
Sign up for free
stock news alerts at Investorideas.com
Contact
Investorideas.com
800 665 0411
No comments:
Post a Comment